2025 United Kingdom Cell Viability Assays Market Revenue Opportunities Report
Description
The 2025 United Kingdom Cell Viability Assays Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell Viability Assays Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK Cell Viability Assays Market are Abcam PLC, Thermo Fisher Scientific Inc., Merck KGaA, and Bio-Rad Laboratories. Abcam PLC, headquartered in Cambridge, UK, is a leading provider of life science reagents including cell viability assay kits, supporting research with products such as antibodies and assay kits tailored for cellular health analysis. Thermo Fisher Scientific, a global leader based in the US, offers a broad portfolio of cell viability reagents and automated instrument platforms including AlamarBlue and PrestoBlue reagents, contributing significantly to both research and clinical applications in the UK. Merck KGaA, operating under MilliporeSigma in North America, supplies advanced assay kits like CellTiter-Glo and CytoTox-One, facilitating drug discovery and cytotoxicity testing. Bio-Rad Laboratories, also US-based but globally present, offers innovative cell counting instruments and viability testing kits widely used in UK research institutions.
These companies dominate the UK market through extensive product lines and strong innovation pipelines addressing various cell viability assay technologies. The UK market itself generated USD 75.5 million in revenue in 2023 and is expected to grow rapidly with a CAGR of 13.4% until 2030, driven by increasing R&D investments, demand for cytotoxicity testing, and adoption of advanced assay platforms. Consumables constitute the largest segment in the UK market, highlighting the demand for reagents and kits supplied by these leading firms. This competitive landscape fosters ongoing advancements and diversification of cell viability assay products tailored to biomedical research and pharmaceutical development needs in the UK and Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cell Viability Assays Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the UK Cell Viability Assays Market are Abcam PLC, Thermo Fisher Scientific Inc., Merck KGaA, and Bio-Rad Laboratories. Abcam PLC, headquartered in Cambridge, UK, is a leading provider of life science reagents including cell viability assay kits, supporting research with products such as antibodies and assay kits tailored for cellular health analysis. Thermo Fisher Scientific, a global leader based in the US, offers a broad portfolio of cell viability reagents and automated instrument platforms including AlamarBlue and PrestoBlue reagents, contributing significantly to both research and clinical applications in the UK. Merck KGaA, operating under MilliporeSigma in North America, supplies advanced assay kits like CellTiter-Glo and CytoTox-One, facilitating drug discovery and cytotoxicity testing. Bio-Rad Laboratories, also US-based but globally present, offers innovative cell counting instruments and viability testing kits widely used in UK research institutions.
These companies dominate the UK market through extensive product lines and strong innovation pipelines addressing various cell viability assay technologies. The UK market itself generated USD 75.5 million in revenue in 2023 and is expected to grow rapidly with a CAGR of 13.4% until 2030, driven by increasing R&D investments, demand for cytotoxicity testing, and adoption of advanced assay platforms. Consumables constitute the largest segment in the UK market, highlighting the demand for reagents and kits supplied by these leading firms. This competitive landscape fosters ongoing advancements and diversification of cell viability assay products tailored to biomedical research and pharmaceutical development needs in the UK and Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
